## **Core Concept**
The core concept here revolves around the management of stroke, specifically focusing on the prevention of recurrent stroke. Alteplase, a tissue plasminogen activator (tPA), is used for acute ischemic stroke treatment to dissolve clots. For long-term prevention of recurrent stroke, antithrombotic therapy is commonly employed.

## **Why the Correct Answer is Right**
The correct answer, , involves the use of antiplatelet agents or anticoagulants for the prevention of recurrent ischemic strokes. Among these, antiplatelet agents like aspirin, clopidogrel, or a combination of both are commonly used for long-term management. Anticoagulants like warfarin or direct oral anticoagulants (DOACs) are preferred in cases of atrial fibrillation-related strokes. The choice between antiplatelet agents and anticoagulants depends on the stroke etiology.

## **Why Each Wrong Option is Incorrect**
- **Option A:** is not typically used for long-term prevention of stroke recurrence. It might be used in certain cases of acute coronary syndromes but not as a first-line agent for stroke prevention.
- **Option B:** could be considered in certain contexts but is not the most universally applied long-term strategy for preventing recurrent strokes compared to antiplatelet therapy or anticoagulation.
- **Option C:** This option might seem plausible but given the context, it is less likely compared to antiplatelet or anticoagulant therapy for long-term stroke prevention.

## **Clinical Pearl / High-Yield Fact**
A key point to remember is that for patients with ischemic stroke due to atrial fibrillation, anticoagulation is generally recommended for long-term prevention, whereas for those with other causes of ischemic stroke, antiplatelet therapy is often the mainstay. The choice of agent (aspirin, clopidogrel, warfarin, DOACs) depends on stroke etiology, risk factors, and patient-specific conditions.

## **Correct Answer:** .